Exelixis Inc
NASDAQ:EXEL
Exelixis Inc
Net Income (Common)
Exelixis Inc
Net Income (Common) Peer Comparison
Competitive Net Income (Common) Analysis
Latest Figures & CAGR of Competitors
Company | Net Income (Common) | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Exelixis Inc
NASDAQ:EXEL
|
Net Income (Common)
$207.8m
|
CAGR 3-Years
23%
|
CAGR 5-Years
-21%
|
CAGR 10-Years
N/A
|
|
Abbvie Inc
NYSE:ABBV
|
Net Income (Common)
$4.8B
|
CAGR 3-Years
2%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
2%
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Net Income (Common)
$5.7B
|
CAGR 3-Years
258%
|
CAGR 5-Years
1%
|
CAGR 10-Years
6%
|
|
Amgen Inc
NASDAQ:AMGN
|
Net Income (Common)
$6.7B
|
CAGR 3-Years
-3%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
3%
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Net Income (Common)
$3.6B
|
CAGR 3-Years
10%
|
CAGR 5-Years
12%
|
CAGR 10-Years
N/A
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Net Income (Common)
$4B
|
CAGR 3-Years
4%
|
CAGR 5-Years
10%
|
CAGR 10-Years
25%
|
See Also
What is Exelixis Inc's Net Income (Common)?
Net Income (Common)
207.8m
USD
Based on the financial report for Dec 29, 2023, Exelixis Inc's Net Income (Common) amounts to 207.8m USD.
What is Exelixis Inc's Net Income (Common) growth rate?
Net Income (Common) CAGR 5Y
-21%
Over the last year, the Net Income (Common) growth was 14%. The average annual Net Income (Common) growth rates for Exelixis Inc have been 23% over the past three years , -21% over the past five years .